Human papillomavirus vaccine and adolescents

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 5, 2008, Pages 447-454

  Dempsey, Amanda F ^a   Zimet, Gregory D ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Adolescents; Human papillomavirus; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ACUTE DISEASE; ADOLESCENT HEALTH; ANUS CANCER; CANCER INCIDENCE; CANCER PREVENTION; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; GENITAL TRACT CANCER; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFORMED CONSENT; LACTATION; LAW; MEDICOLEGAL ASPECT; PAPANICOLAOU TEST; PARENT; PARENTAL CONSENT; PATIENT CARE; PATIENT COMPLIANCE; PRECANCER; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; SCHOOL HEALTH SERVICE; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VIRUS INFECTION; VULVA CANCER; WART VIRUS;

ADOLESCENT; ADOLESCENT MEDICINE; ADULT; CHILD; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; MASS IMMUNIZATION; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK; SCHOOLS; YOUNG ADULT;

EID: 55349120159     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3283086719     Document Type: Review

References (106)

1. Moscicki AB, Burt VG, Kanowitz S, et al. The significance of squamous metaplasia in the development of low grade squamous intraepithelial lesions in young women. Cancer 1999; 85:1139-1144.
2. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285:2995-3002.
3. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24 (Suppl 3):S42-S51.
4. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-428.
5. Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis 2006; 33:502-508.
6. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002; 29:725-735.
7. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 2004; 189:46-50.
8. Winer RL, Feng Q, Hughes JP, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008; 197:279-282. This review describes HPV infection prevalence among a cohort of college-aged women who initiated sexual activity during the study period. It provides compelling evidence that even having only one lifetime sexual partner places women at a substantial risk for HPV infection.
9. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002; 94:1406-1414.
10. Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004; 36:6-10.
11. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297:813-819. This is a seminal study that uses data obtained for the National Health and Nutrition Examination Survey to provide national-level estimates of HPV infection for the first time. Consistent with other smaller studies, this study demonstrates that HPV infection has the highest prevalence among adolescents and young adults.
12. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005; 191:182-192.
13. U.S. Food and Drug Administration. Product approval information: licensing action, Gardasil. http://www.fda.gov/cber/products/hpvmer060806qa.htm. [Accessed 1 August 2006].
14. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1-24. This review describes the official guidelines for HPV vaccine utilization set forth by the Advisory Committee on Immunization Practices.
15. Glaxo's Cervairx vaccine gets standard FDA review. Reuters 31 May 2007.
16. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-1765.
17. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-1255.
18. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-278.
19. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-1466.
20. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369:1861-1868.
21. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-2170.
22. Perez G, Lazcano-Ponce E, Hernandez-Avila M, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 2008; 122:1311-1318.
23. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40:564-571.
24. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007; 26:201-209.
25. Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3:e138.
26. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13:28-41.
27. Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106:896-904.
28. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human paplllomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96:604-615.
29. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290:781-789.
30. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9:37-48.
31. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10:1915-1923.
32. National Cancer Institute. Surveillance epidemiology and end results, Cancer Query Systems. http://seer.cancer.gov/canques/. [Accessed 25 March 2008].
33. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36:1397-1403.
34. Mount SL, Papillo JL. A study of 10296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics 1999; 103:539-545.
35. Insinga RP, Dasbach EJ, Elbasha EH, et al. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007; 16:709-715.
36. Insinga RP, Dasbach EJ, Elbasha EH, et al. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007; 26:128-139.
37. Institute of Medicine. Vaccines for the 21st century: a tool for decisionmaking. In: Stratton KR Durch KS, Lawrence RS, editors. Washington DC: Institute of Medicine; 1999. pp. 213-220.
38. Brisson M, Van de Velde N, De Wals P, Bolly MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25:5399-5408.
39. American Academy of Pediatrics Committee on Infectious Diseases. Recommended immunization schedules for children and adolescents: United States, 2008. Pediatrics 2008; 121:219-220.
40. Szilagyi PG, Rand CM, McLaurin J, et al. Delivering adolescent vaccinations in the medical home: a new era? Pediatrics 2008; 121 (Suppl 1):S15-S24. This review article, part of a special supplement related to adolescent vaccination, describes what is currently known about adolescent healthcare utilization and identifies important gaps in this understanding that impact adolescent vaccination delivery.
41. Kottke TE, Solberg LI, Brekke ML, et al. Delivery rates for preventive services in 44 midwestern clinics. Mayo Clin Proc 1997; 72:515-523.
42. Schaffer SJ, Fontanesi J, Rickert D, et al. How effectively can healthcare settings beyond the traditional medical home provide vaccines to adolescents? Pediatrics 2008; 121 (Suppl 1):S35-S45.
43. Schaffer SJ, Humiston SG, Shone LP, et al. Adolescent immunization practices: a national survey of US physicians. Arch Pediatr Adolesc Med 2001; 155:566-571.
44. Halpern-Felsher BL, Ozer EM, Millstein SG, et al. Preventive services in a health maintenance organization: how well do pediatricians screen and educate adolescent patients? Arch Pediatr Adolesc Med 2000; 154: 173-179.
45. Broder KR, Cohn AC, Schwartz B, et al. Adolescent immunizations and other clinical preventive services: a needle and a hook? Pediatrics 2008; 121 (Suppl 1):S25-S34. This review article, also part of a special supplement on adolescent immunization, describes how adolescent immunization-related visits might be used to provide additional preventive-care services to this population.
46. Rand CM, Shone LP, Albertin C, et al. National healthcare visit patterns of adolescents: implications for delivery of new adolescent vaccines. Arch Pediatr Adolesc Med 2007; 161:252-259.
47. Gonik B, Fasano N, Foster S. The obstetrician-gynecologist's role in adult immunization. Am J Obstet Gynecol 2002; 187:984-988.
48. Kane M. Chapter 9: delivering HPV vaccine in the industrial and developing world: the role of the ob-gyn community. Int J Gynaecol Obstet 2006; 94 (Suppl 1):S89-S94.
49. Elster AB, Kuznets NJ. American Medical Association: guidelines for adolescent preventive services (GAPS). Baltimore: Williams and Wilkins; 1994.
50. Green M, Palfrey J. Bright futures: guidelines for health supervision of infants, children, and adolescents. 2nd revised ed. Arlington: National Center for Education in Maternal and Child Health; 2002.
51. American Academy of Pediatrics CoPAoCaFH. Recommendations for preventive pediatric healthcare. http://aappolicy.aappublications.org/cgi/content/full/ pediatrics%3b105/3/645. [Accessed 30 March 2008].
52. Middleman AB, Rosenthal SL, Rickert VI, et al. Adolescent immunizations: a position paper of the Society for Adolescent Medicine. J Adolesc Health 2006; 38:321-327.
53. Peter G, Gardner P. Standards for immunization practice for vaccines in children and adults. Infect Dis Clin North Am 2001; 15:9-19.
54. Rupp R, Rosenthal SL, Middleman AB. Vaccination: an opportunity to enhance early adolescent preventive services. J Adolesc Health 2006; 39:461-464.
55. English A, Shaw FE, McCauley MM, Fishbein DB. Legal basis of consent for healthcare and vaccination for adolescents. Pediatrics 2008; 121 (Suppl 1): S85-S87. This review, also part of a special supplement on adolescent immunization, provides an exceptionally cogent description of minor consent laws and how these impact adolescent immunization delivery.
56. Gordon TE, Zook EG, Averhoff FM, Williams WW. Consent for adolescent vaccination: issues and current practices. J Sch Health 1997; 67:259-264.
57. Cassidy WM, Mahoney FJ. A hepatitis B vaccination program targeting adolescents. J Adolesc Health 1995; 17:244-247.
58. Wilson T, Harman S. Analysis of a bi-state, multidistrict, school-based hepatitis B immunization program. J Sch Health 2000; 70:408-412.
59. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007; 45:107.
60. Zimet GD. Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health 2005; 37 (6 Suppl 1):S17.
61. Zimet GD, Liddon N, Rosenthal SL, et al. Chapter 24: psychosocial aspects of vaccine acceptability. Vaccine 2006; 24 (Suppl 3):S201-S209.
62. Zimet GD, Shew ML, Kahn JA. Appropriate use of cervical cancer vaccine. Ann Rev Med 2008; 59:223.
63. Bair RM, Mays RM, Sturm LA, et al. Acceptability to Latino parents of sexually transmitted infection vaccination. Amb Pediatrics 2008; 9:98.
64. Chan SSC, Cheung TH, Lo WK, Chung TKH. Women's attitudes on human papillomavirus vaccination to their daughters. J Adolesc Health 2007; 41:204.
65. Gerend MA, Cruz Lee S, Shepherd JE. Predictors of human papillomavirus vaccination acceptability among underserved women. Sex Transm Dis 2007; 34:468.
66. Hausdorf K, Newman B, Whiteman D, et al. HPV vaccination: what do Queensland parents think? Aust N Z J Public Health 2007; 31:288.
67. Hopenhayn C, Christian A, Christian WJ, Schoenberg NE. Human papillomavirus vaccine: knowledge and attitudes in two Appalachian Kentucky counties. Cancer Causes Control 2007; 18:627.
68. Lee PWH, Kwan TTC, Tam KF, et al. Beliefs about cervical cancer and human papillomavirus (HPV) and acceptability of HPV vaccination among Chinese women in Hong Kong. Prev Med 2007; 45:130.
69. Marlow LAV, Waller J, Wardle J. Parental attitudes to prepubertal HPV vaccination. Vaccine 2007; 25:1945.
70. Marlow LAV, Waller J, Wardle J. Trust and experience as predictors of HPV vaccine acceptance. Hum Vacc 2007; 3:171.
71. Marshall H, Ryan P, Roberton D, Baghurst P. A cross-sectional survey to assess community attitudes to introduction of human papillomavirus vaccine. Aust N Z J Public Health 2007; 31:235.
72. Ogilvie GS, Remple VP, Marra F, et al. Parental intention to have daughters receive the human papillomavirus vaccine. CMAJ 2007; 177:1506. This large-scale, nation-wide Canadian study looked at factors predictive of parents' intentions to have their daughters vaccinated against HPV.
73. Sauvageau C, Duval B, Gilca V, et al. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 2007; 7:304.
74. Sperber NR, Brewer NT, Smith JS. Influence of parent characteristics and disease outcome framing on HPV vaccine acceptability among rural, southern women. Cancer Causes Control 2008; 19:115.
75. Stewart A, O'Mahony C. Public perception of human papillomavirus vaccine. Int J STD AIDS 2007; 18:505.
76. Bair RM, Mays RM, Sturm LA, Zimet GD. Acceptability of the human papillomavirus vaccine among Latina mothers. J Pediatr Adolesc Gynecol (in press).
77. Baykal C, Ai A, Ugur MG, et al. Knowledge and interest of Turkish women about cervical cancer and HPV vaccine. Eur J Gynaecol Oncol 2008; 29:76.
78. Crosby R, Schoenberg N, Hopenhayn C, et al. Correlates of intent to be vaccinated against human papillomavirus: an exploratory study of college-aged women. Sex Health 2007; 4:71.
79. Gerend MA, Shepherd JE. Using message framing to promote acceptance of the human papillomavirus vaccine. Health Psychol 2007; 26:745. This study tested the effects of brief message-framing interventions on attitudes about HPV vaccination.
80. Gerend MA, Magloire ZF. Awareness, knowledge, and beliefs about human papillomavirus in a racially diverse sample of young adults. J Adolesc Health 2008; 42:237.
81. Kahn JA, Rosenthal SL, Jin Y, et al. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obst Gyn 2008; 111:1103-1110. This study is among the first to look at postlicensure attitudes about HPV vaccination.
82. McClelland A, Liamputtong P. Knowledge and acceptance of human papillomavirus vaccination: perspectives of young Australians living in Melbourne, Australia Sex Health 2006; 3:95.
83. Moreira ED Jr, de Oliveira BG, Neves RCS, et al. Assessment of knowledge and attitudes of young uninsured women toward human papillomavirus vaccination and clinical trials. J Pediatr Adolesc Gynecol 2006; 19:81.
84. Duval B, Gilca V, McNeil S, et al. Vaccination against human papillomavirus: a baseline survey of Canadian clinicians' knowledge, attitudes and beliefs. Vaccine 2007; 25:7841-7847.
85. Esposito S, Bosis S, Pelucchi C, et al. Pediatrician knowledge and attitudes regarding human papillomavirus disease and its prevention. Vaccine 2007; 25:6437.
86. Kahn JA, Rosenthal SL, Tissot AM, et al. Factors influencing pediatricians' intention to recommend human papillomavirus vaccines. Amb Pediatrics 2007; 7:367.
87. Sussman AL, Helitzer D, Sanders M, et al. HPV and cervical cancer prevention counseling with younger adolescents: implications for primary care. Ann Fam Med 2007; 5:298.
88. Calloway C, Jorgensen CM, Saraiya M, Tsui J. A content analysis of news coverage of the HPV vaccine by U.S. newspapers, January 2002-June 2005. J Wom Health 2006; 15:803.
89. Siegrist CA, Lewis EM, Eskola J, et al. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007; 26:979. Anticipating the possibility that certain medical problems may be falsely attributed to HPV vaccination, this study attempts to prospectively identify the kind of medical issues that would tend to occur in temporal association with HPV vaccination.
90. Donders GGG, Gabrovska M, Bellen G, et al. Knowledge of cervix cancer, human papilloma virus (HPV) and HPV vaccination at the moment of introduction of the vaccine in women in Belgium. Arch Gynecol Obstet 2008; 277:291.
91. Vrscaj MU, Vakselj A, Strzinar V, et al. Knowledge about and attitudes to Pap smears, cervical cancer and human papillomavirus among women in Slovenia. Eur J Gynaecol Oncol 2008; 29:148.
92. Ferris DG, Waller JL, Owen A, Smith J. Midadult women's attitudes about receiving the prophylactic human papillomavirus vaccine. J Low Genit Tract Dis 2007; 11:166.
93. Charo RA. Politics, parents, and prophylaxis: mandating HPV vaccination in the United States. N Engl J Med 2007; 356:1905.
94. Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med 2006; 355:2389.
95. Gostin LO, DeAngelis CD. Mandatory HPV vaccination: public health vs private wealth. JAMA 2007; 297:1921.
96. Haber G, Malow RM, Zimet GD. The HPV vaccine mandate controversy. J Pediatr Adolesc Gynecol 2007; 20:325. This commentary reviews and evaluates many of the arguments for and against school-entry requirements for HPV vaccine.
97. Schwartz JL, Caplan AL, Faden RR, Sugarman J. Lessons from the failure of human papillomavirus vaccine state requirements. Clin Pharmacol Ther 2007; 82:760. This commentary critically reviews the controversy over HPV vaccine legislation and identifies some of the deleterious effects of the push to pass such legislation.
98. Stewart AM. Mandating HPV vaccination: private rights, public good. N Engl J Med 2007; 356:1998.
99. Zimmerman RK. Ethical analysis of HPV vaccine policy options. Vaccine 2006; 24:4812.
100. Hinman AR, Orenstein WA, Williamson DE, Darrington D. Childhood immunization: laws that work. J Law Med Ethics 2002; 30 (Suppl):122.
101. Feikin DR, Lezotte DC, Hamman RF, et al. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA 2000; 284:3145.
102. Omer SB, Pan WKY, Halsey NA, et al. Nonmedical exemptions to school immunization requirements. JAMA 2006; 296:1757.
103. Thompson JW, Tyson S, Card-Higginson P, et al. Impact of addition of philosophical exemptions on childhood immunization rates. Am J Prev Med 2007; 32:194.
104. National Conference of State Legislators. HPV vaccine legislation 2007-2008. http://www.ncsl.org/programs/health/HPVvaccine.htm. [Accessed 28 April 2008]. This website periodically updates, on a state-by-state basis, the legislation being considered regarding HPV vaccination, including links to the proposed legislation.
105. Association of Immunization Managers. Position statement: school and child care immunization requirements. 2006. http://www.immunizationmanagers.org/ pdfs/SchoolrequirementsFINALpdf. [Accessed 20 March 2007].
106. Zimet GD, Maehr J, Constantine NA, English A. School-entry vaccination requirements: a position statement of the Society for Adolescent Medicine. J Adolesc Health 2008; 42:310.